August 1st 2025
The biomarker analysis in KEYNOTE-426 showed that pembrolizumab plus axitinib therapy is associated with positive outcomes with angiogenesis in RCC.
Combination Immunotherapy Shows Early Promise Against Kidney, Lung Cancer
September 29th 2016Combining two cancer immunotherapies to target both the interleukin 10 (IL-10) and programmed cell death protein 1 (PD-1) receptors has yielded promising early results for some patients with renal cell carcinoma and non-small cell lung cancer.
Third-Line Treatment Options for Kidney Cancer
September 15th 2016Effectively, the field has tested agents for metastatic disease in only two clinical settings: primary management of metastatic disease (first-line) and after progression with a first-line therapy (second-line); however, there are no category 1 data that support the use of any agent in the third-line setting.
Nephrectomy, Hepatic Resection Possible Safe Aggressive Approach for RCC
September 5th 2016Patients with RCC who underwent simultaneous nephrectomy and hepatic resection had similar postoperative mortality, long-term survival, and cancer-specific survival as those patients who underwent metastasectomy or en bloc resection of neighboring non-hepatic organs.
Despite Preclinical Findings, ‘Much More Work’ Needed for RCC Biomarkers
September 1st 2016Despite treatment advances for renal cell carcinoma, biomarkers are urgently needed for earlier diagnosis and treatment, and quicker assessment of treatment efficacy. Development of such tools has lagged behind biomarker research for more common cancers, and despite encouraging findings from several newly published preclinical studies.
Pneumonitis Incidence From PD-1 Inhibitors Higher in NSCLC, RCC
August 31st 2016Although the overall incidence of programmed cell death 1 (PD-1) inhibitor-related pneumonitis is rare, the serious adverse event may occur more commonly in certain solid tumor types like non–small-cell lung cancer and renal cell carcinoma.
Contemporary Management of Small Renal Masses
June 15th 2016Despite improved understanding of the molecular features of renal tumors, increasing expertise in surgical management of localized renal cancers, and multiple effective systemic therapies for metastatic cancer, mortality from renal cell carcinoma remains largely unchanged.